Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer

Background: Immune checkpoint inhibitors (ICIs) are effective for NSCLC, but patients with NSCLC and EGFR mutations are less likely to benefit from ICI treatment. A small subset of patients harboring EGFR mutations is reported to respond to the treatment, although no biomarkers have been identified....

ver descrição completa

Detalhes bibliográficos

Principais autores:	Koichi Azuma, Mitsuo Osuga, Shoichi Itoh, Yoshitaka Kawa, Toshiyuki Kozuki, Yukihiro Toi, Kenta Murotani, Motohiro Izumi, Daiki Murata, Akito Hata, Shunichi Sugawara, Miyako Satouchi, Nobuyuki Yamamoto, Yasuhiro Koh
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-01-01
Colecção:	Cancer Treatment and Research Communications
Assuntos:	NSCLC PD-1 inhibitor Biomarker EGFR mutation
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2468294226000389
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!